DK4104687T5 - Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe - Google Patents
Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe Download PDFInfo
- Publication number
- DK4104687T5 DK4104687T5 DK22175377.5T DK22175377T DK4104687T5 DK 4104687 T5 DK4104687 T5 DK 4104687T5 DK 22175377 T DK22175377 T DK 22175377T DK 4104687 T5 DK4104687 T5 DK 4104687T5
- Authority
- DK
- Denmark
- Prior art keywords
- rnas
- synthesizing
- compositions
- coated
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/336—Modified G
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562221248P | 2015-09-21 | 2015-09-21 | |
| EP21173278.9A EP3906789B1 (en) | 2015-09-21 | 2016-09-20 | Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK4104687T3 DK4104687T3 (da) | 2024-03-04 |
| DK4104687T5 true DK4104687T5 (da) | 2024-07-22 |
Family
ID=58387109
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24186081.6T DK4424835T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe |
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK22175377.5T DK4104687T5 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe |
| DK22190426.1T DK4140491T5 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK24186081.6T DK4424835T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntesering af 5'-ende RNA'er med kappe |
| DK21173142.7T DK3954225T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
| DK16849423.5T DK3352584T3 (da) | 2015-09-21 | 2016-09-20 | Sammensætninger og fremgangsmåder til syntese af 5'-rna¿er med kappe |
| DK21173278.9T DK3906789T5 (da) | 2015-09-21 | 2016-09-20 | Initierende oligonukleotidprimere med kappe til syntetisering af RNA med 5'-kappe |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK22190426.1T DK4140491T5 (da) | 2015-09-21 | 2016-09-20 | Fremgangsmåde til syntetisering af RNA'er med 5'-kappe |
Country Status (21)
| Country | Link |
|---|---|
| US (9) | US10913768B2 (da) |
| EP (9) | EP3906789B1 (da) |
| JP (4) | JP6814997B2 (da) |
| KR (3) | KR102670937B1 (da) |
| CN (8) | CN116751827B (da) |
| AU (5) | AU2016328645C1 (da) |
| CA (2) | CA2999274C (da) |
| CY (1) | CY1124306T1 (da) |
| DK (6) | DK4424835T3 (da) |
| ES (5) | ES2964690T3 (da) |
| FI (5) | FI4424835T3 (da) |
| HK (1) | HK1255236A1 (da) |
| HR (1) | HRP20211091T1 (da) |
| HU (5) | HUE055458T2 (da) |
| LT (6) | LT3954225T (da) |
| PL (5) | PL3906789T3 (da) |
| PT (6) | PT4424835T (da) |
| RS (1) | RS62129B1 (da) |
| SI (5) | SI4104687T1 (da) |
| SM (1) | SMT202100396T1 (da) |
| WO (1) | WO2017053297A1 (da) |
Families Citing this family (211)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201912038TA (en) | 2014-04-23 | 2020-02-27 | Modernatx Inc | Nucleic acid vaccines |
| ES2964690T3 (es) * | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| JP2019500899A (ja) | 2015-11-23 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作 |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| JP2020508056A (ja) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ | 遺伝子編集のための組成物および方法 |
| AU2018240515B2 (en) | 2017-03-24 | 2024-07-25 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| EP3622062A4 (en) | 2017-05-10 | 2020-10-14 | The Regents of the University of California | DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9 |
| CN111417724A (zh) | 2017-06-30 | 2020-07-14 | 科德克希思公司 | T7 rna聚合酶变体 |
| US10793841B2 (en) * | 2017-06-30 | 2020-10-06 | Codexis, Inc. | T7 RNA polymerase variants |
| RU2020103379A (ru) | 2017-07-04 | 2021-08-04 | Куревак Аг | Новые молекулы нуклеиновых кислот |
| ES2983060T3 (es) | 2017-08-18 | 2024-10-21 | Modernatx Inc | Variantes de ARN polimerasa |
| US11602557B2 (en) | 2017-08-22 | 2023-03-14 | Cure Vac SE | Bunyavirales vaccine |
| EP3688161A1 (en) | 2017-09-29 | 2020-08-05 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis |
| AR113154A1 (es) | 2017-09-29 | 2020-01-29 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para edición del genoma |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| WO2019193183A2 (en) | 2018-04-05 | 2019-10-10 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| CA3091558A1 (en) | 2018-04-17 | 2019-10-24 | Curevac Ag | Novel rsv rna molecules and compositions for vaccination |
| WO2020002525A1 (en) | 2018-06-27 | 2020-01-02 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| BR112020025601A8 (pt) | 2018-06-28 | 2022-07-05 | Tesla Automation GmbH | Biorreator para a transcrição in vitro de rna |
| JP7445657B2 (ja) | 2018-12-06 | 2024-03-07 | アークトゥラス・セラピューティクス・インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症を処置するための組成物および方法 |
| US12492425B2 (en) | 2018-12-21 | 2025-12-09 | CureVac SE | Methods for RNA analysis |
| CA3118034A1 (en) | 2018-12-21 | 2020-06-25 | Curevac Ag | Rna for malaria vaccines |
| US20220133908A1 (en) | 2019-02-08 | 2022-05-05 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophthalmic diseases |
| AU2020220357B2 (en) | 2019-02-11 | 2025-06-26 | Ethris Gmbh | mRNA purification by tangential flow filtration |
| CN113795579A (zh) | 2019-02-20 | 2021-12-14 | 摩登纳特斯有限公司 | 用于共转录加帽的rna聚合酶变体 |
| CA3132975A1 (en) | 2019-03-11 | 2020-09-17 | Modernatx, Inc. | Fed-batch in vitro transcription process |
| AU2020248337A1 (en) | 2019-03-28 | 2021-11-04 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating ATTR amyloidosis comprising a corticosteroid or use thereof |
| EP3946598A1 (en) | 2019-03-28 | 2022-02-09 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
| BR112021019224A2 (pt) | 2019-03-28 | 2021-11-30 | Intellia Therapeutics Inc | Polinucleotídeos, composições e métodos para expressão de polipeptídeo |
| WO2020214806A1 (en) * | 2019-04-16 | 2020-10-22 | The Regents Of The University Of California | Protein translational control |
| US20220362360A1 (en) * | 2019-04-26 | 2022-11-17 | Etherna Immunotherapies Nv | Mrna formulation |
| CN114126668A (zh) * | 2019-05-24 | 2022-03-01 | 超基因制药股份有限公司 | 用于血色素沉积症治疗的组合物和方法 |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| US20220313813A1 (en) | 2019-06-18 | 2022-10-06 | Curevac Ag | Rotavirus mrna vaccine |
| EP4003508A1 (en) | 2019-07-31 | 2022-06-01 | Memorial Sloan Kettering Cancer Center | Perfusion modulated tumor dose sculpting with single dose radiotherapy |
| EP4013880A1 (en) | 2019-08-14 | 2022-06-22 | CureVac AG | Rna combinations and compositions with decreased immunostimulatory properties |
| JP2022546417A (ja) * | 2019-08-29 | 2022-11-04 | チューリッヒ大学 | 最小ｍＲＮＡおよびその使用 |
| KR20220121246A (ko) | 2019-12-20 | 2022-08-31 | 큐어백 아게 | 핵산 전달용 신규한 지질 나노입자 |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| MX2022009460A (es) | 2020-02-04 | 2022-12-16 | Curevac Ag | Vacuna contra el coronavirus. |
| PL248416B1 (pl) * | 2020-02-12 | 2025-12-08 | Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| EP4112630B1 (en) | 2020-02-28 | 2024-10-16 | Japan Science and Technology Agency | Method for producing capped rna |
| CN113151312B (zh) * | 2020-03-02 | 2022-12-09 | 中国科学院微生物研究所 | 新型冠状病毒SARS-CoV-2 mRNA疫苗及其制备方法和应用 |
| JP7832114B2 (ja) | 2020-03-03 | 2026-03-17 | アークトゥラス・セラピューティクス・インコーポレイテッド | オルニチントランスカルバミラーゼ欠損症の治療のための組成物及び方法 |
| WO2021183563A1 (en) | 2020-03-09 | 2021-09-16 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| WO2021198157A1 (en) | 2020-03-30 | 2021-10-07 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2021216776A2 (en) | 2020-04-21 | 2021-10-28 | Gritstone Bio, Inc. | Capping compounds, compositions and methods of use thereof |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| US12070509B2 (en) | 2020-05-01 | 2024-08-27 | Arcturus Therapeutics, Inc. | Nucleic acids and methods of treatment for cystic fibrosis |
| CN115916978A (zh) | 2020-05-19 | 2023-04-04 | 哈德森医学研究所 | 寡核苷酸 |
| MX2022015132A (es) | 2020-05-29 | 2023-03-08 | CureVac SE | Vacunas combinadas a base de acidos nucleicos. |
| KR20230034333A (ko) * | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| CN113416762A (zh) * | 2020-08-20 | 2021-09-21 | 深圳市瑞吉生物科技有限公司 | 一种Cap2结构5′帽子类似物及其制备方法和应用 |
| CA3170743A1 (en) | 2020-08-31 | 2022-03-03 | Susanne RAUCH | Multivalent nucleic acid based coronavirus vaccines |
| US20240246056A1 (en) | 2020-09-01 | 2024-07-25 | CureVac RNA Printer GmbH | Manufacturing device for a pharmaceutical product |
| CN116368226A (zh) | 2020-09-04 | 2023-06-30 | 维乎医疗有限公司 | 用于加帽rna的组合物和方法 |
| KR102366490B1 (ko) | 2020-10-20 | 2022-02-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| JP7641487B2 (ja) | 2020-11-27 | 2025-03-07 | キュアバック マニュファクチャリング ゲーエムベーハー | キャピラリーポリメラーゼ連鎖反応によってｄｎａ産物を調製するためのデバイス |
| AU2021395736A1 (en) | 2020-12-09 | 2023-07-27 | BioNTech SE | Rna manufacturing |
| CR20230305A (es) | 2020-12-11 | 2023-11-10 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación |
| US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| WO2022135993A2 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| US20240316090A1 (en) | 2020-12-28 | 2024-09-26 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| WO2022162027A2 (en) | 2021-01-27 | 2022-08-04 | Curevac Ag | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| TW202241508A (zh) | 2021-01-29 | 2022-11-01 | 美商艾歐凡斯生物治療公司 | 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法 |
| WO2022175815A1 (en) | 2021-02-19 | 2022-08-25 | Pfizer Inc. | Methods of protecting rna |
| US20240181037A1 (en) | 2021-03-26 | 2024-06-06 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
| EP4312988A2 (en) | 2021-03-31 | 2024-02-07 | CureVac SE | Syringes containing pharmaceutical compositions comprising rna |
| KR20220140140A (ko) | 2021-04-09 | 2022-10-18 | 한미정밀화학주식회사 | 캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도 |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| US20240321387A1 (en) | 2021-05-04 | 2024-09-26 | BioNTech SE | Immunogen selection |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| KR20240038705A (ko) | 2021-06-22 | 2024-03-25 | 인텔리아 테라퓨틱스, 인크. | 간 유전자의 생체 내 편집 방법 |
| CN117858885A (zh) | 2021-07-05 | 2024-04-09 | 国立研究开发法人科学技术振兴机构 | 核苷酸类的纯化方法和核苷酸类的纯化装置以及疏水性试剂和疏水性底物 |
| EP4116313A1 (en) | 2021-07-07 | 2023-01-11 | Westfälische Wilhelms-Universität Münster | Cap analog for the 5'-end of eukaryotic messenger rnas |
| WO2023006920A1 (en) | 2021-07-29 | 2023-02-02 | BioNTech SE | Compositions and methods for treatment of melanoma |
| CA3171750A1 (en) | 2021-07-30 | 2023-02-02 | Tim SONNTAG | Mrnas for treatment or prophylaxis of liver diseases |
| EP4377326A1 (en) | 2021-07-30 | 2024-06-05 | CureVac SE | Cap analogs having an acyclic linker to the guanine derivative nucleobase |
| JP2024534120A (ja) | 2021-08-24 | 2024-09-18 | ビオンテック・ソシエタス・エウロパエア | インビトロ転写技術 |
| CN118978560A (zh) | 2021-08-27 | 2024-11-19 | 上海兆维科技发展有限公司 | 一种加帽类似物及其应用 |
| AU2022338639A1 (en) | 2021-08-31 | 2024-02-08 | Hanmi Fine Chemical Co., Ltd. | Mrna cap analogue and use thereof |
| WO2023031392A2 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine |
| MX2024002726A (es) | 2021-09-03 | 2024-03-20 | CureVac SE | Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos. |
| CN113957108B (zh) * | 2021-09-09 | 2025-01-10 | 上海兆维科技发展有限公司 | 一种加帽rna的合成方法以及加帽rna转录反应液 |
| WO2023067125A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| JP2024540979A (ja) | 2021-10-22 | 2024-11-06 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖複合体及び用途 |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067126A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| JP2024543247A (ja) | 2021-10-22 | 2024-11-20 | ビオンテック・ソシエタス・エウロパエア | オリゴ糖化合物及び複合体 |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4402149A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| WO2023073228A1 (en) | 2021-10-29 | 2023-05-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| EP4426822A2 (en) | 2021-11-03 | 2024-09-11 | Intellia Therapeutics, Inc. | Polynucleotides, compositions, and methods for genome editing |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| KR20230083197A (ko) | 2021-12-01 | 2023-06-09 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| WO2023115495A1 (zh) * | 2021-12-23 | 2023-06-29 | 北京毅新博创生物科技有限公司 | 质谱法检测mRNA加帽效率的方法 |
| WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| KR20230123318A (ko) | 2022-02-16 | 2023-08-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
| GB2615784A (en) | 2022-02-18 | 2023-08-23 | Phion Therapeutics Ltd | mRNA vaccine |
| JP7642260B2 (ja) | 2022-02-28 | 2025-03-10 | ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 | Ｒｎａキャッピング用化合物及びその使用 |
| CN115260264B (zh) | 2022-02-28 | 2023-06-09 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| JP2025507894A (ja) * | 2022-03-01 | 2025-03-21 | ヴァーヴ・セラピューティクス，インコーポレーテッド | Ｒｎａをキャッピングするための組成物及び方法 |
| CN119053705A (zh) | 2022-03-21 | 2024-11-29 | 克里斯珀医疗股份公司 | 用于治疗脂蛋白相关疾病的方法和组合物 |
| AU2023241456A1 (en) * | 2022-03-31 | 2024-09-05 | Hanmi Fine Chemical Co., Ltd. | Mrna cap analog and uses thereof |
| CN114685588B (zh) * | 2022-05-05 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含开环核苷结构的起始加帽寡核苷酸引物 |
| GB2618818A (en) | 2022-05-18 | 2023-11-22 | Phion Therapeutics Ltd | Vaccine |
| WO2023227608A1 (en) | 2022-05-25 | 2023-11-30 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| US20250375534A1 (en) | 2022-05-30 | 2025-12-11 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2023235422A2 (en) * | 2022-05-31 | 2023-12-07 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| WO2023235362A1 (en) * | 2022-05-31 | 2023-12-07 | Nutcracker Therapeutics, Inc. | Rna cap analogs and methods of use |
| CN119384498A (zh) | 2022-06-16 | 2025-01-28 | 因特利亚治疗公司 | 用于对细胞进行遗传修饰的方法和组合物 |
| WO2023246860A1 (zh) * | 2022-06-22 | 2023-12-28 | 江苏申基生物科技有限公司 | 一种起始加帽寡核苷酸引物及其制备方法和应用 |
| CN114853836B (zh) * | 2022-06-24 | 2024-05-14 | 江苏申基生物科技有限公司 | 一种含gna结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115057903B (zh) * | 2022-06-22 | 2024-03-29 | 江苏申基生物科技有限公司 | 一种含吗啉环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| CN115109110B (zh) * | 2022-06-22 | 2024-07-12 | 江苏申基生物科技有限公司 | 一种含六元糖环结构的起始加帽寡核苷酸引物及其制备方法和应用 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN114941018B (zh) * | 2022-06-28 | 2023-09-22 | 翌圣生物科技(上海)股份有限公司 | cap1帽类似物的合成方法 |
| KR20240010238A (ko) | 2022-07-15 | 2024-01-23 | 한미정밀화학주식회사 | 캡 유사체 및 이의 용도 |
| CN117430652A (zh) * | 2022-07-22 | 2024-01-23 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的环状取代化合物及其应用 |
| US11898186B1 (en) | 2022-08-10 | 2024-02-13 | Genscript Usa Inc. | Compositions and methods for preparing capped mRNA |
| CN115925773A (zh) * | 2022-08-23 | 2023-04-07 | 合肥华纳生物医药科技有限公司 | 一种新型信使核糖核酸帽类似物 |
| CN120129688A (zh) * | 2022-08-26 | 2025-06-10 | 垂林克生物技术有限公司 | 用于制备高度纯化的5′-加帽寡核苷酸的高效方法 |
| WO2024051696A1 (zh) * | 2022-09-05 | 2024-03-14 | 广州市恒诺康医药科技有限公司 | 用于rna加帽的化合物及其应用 |
| EP4583890A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| EP4583889A1 (en) | 2022-09-09 | 2025-07-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| JP2025532191A (ja) | 2022-09-26 | 2025-09-29 | ビオンテック・ソシエタス・エウロパエア | 核酸複合体及びその使用 |
| CN119947747A (zh) | 2022-09-26 | 2025-05-06 | 葛兰素史克生物有限公司 | 流感病毒疫苗 |
| IL319652A (en) | 2022-10-04 | 2025-05-01 | BioNTech SE | RNA structures and their uses |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| CN120129702A (zh) | 2022-10-06 | 2025-06-10 | 生物技术公司 | 靶向密蛋白-18.2的rna组合物 |
| EP4605010A1 (en) | 2022-10-21 | 2025-08-27 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024089229A1 (en) | 2022-10-28 | 2024-05-02 | CureVac SE | Improved formulations comprising lipid-based carriers encapsulating rna |
| CN116143855B (zh) * | 2022-11-08 | 2023-11-28 | 江苏申基生物科技有限公司 | 一种乙烯基膦酸修饰的mRNA帽类似物及其制备方法和应用 |
| WO2024138115A1 (en) | 2022-12-23 | 2024-06-27 | Intellia Theraperutics, Inc. | Systems and methods for genomic editing |
| EP4397669A1 (en) | 2023-01-06 | 2024-07-10 | Westfälische Wilhelms-Universität Münster | Photocaged cap analogs for the 5'-end of rnas |
| TW202444408A (zh) | 2023-01-20 | 2024-11-16 | 瑞典商阿斯特捷利康公司 | 疫苗 |
| IL322194A (en) | 2023-01-20 | 2025-09-01 | Astrazeneca Ab | Nucleic acid molecules |
| WO2024160895A1 (en) | 2023-01-31 | 2024-08-08 | CureVac SE | Cap analogs with 5'-terminal acyclic guanosine derivative |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| WO2024185734A1 (ja) | 2023-03-03 | 2024-09-12 | 株式会社ナティアス | ポリリン酸化ヌクレオシド、ポリリン酸化ヌクレオシドの合成に用いられるリン酸部活性化ヌクレオチド及びその合成方法、ならびにリン酸部活性化ヌクレオチドを用いたポリリン酸化ヌクレオシドの合成方法 |
| KR20250153298A (ko) | 2023-03-08 | 2025-10-24 | 큐어백 에스이 | 핵산 전달을 위한 신규의 지질 나노입자 제형 |
| CN116356002A (zh) * | 2023-03-28 | 2023-06-30 | 四川康德赛医疗科技有限公司 | 一种rna加帽效率的定量方法、试剂盒及其应用 |
| WO2024206565A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Repressor fusion protein systems |
| TW202444906A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 用於靶向pcsk9之組合物及方法 |
| CN118726510A (zh) * | 2023-03-31 | 2024-10-01 | 苏州近岸蛋白质科技股份有限公司 | 一管法酶促合成加帽mRNA的方法 |
| CN118772219B (zh) * | 2023-04-04 | 2025-12-02 | 深圳瑞吉生物科技有限公司 | 一种用于核酸的5’端加帽的含卤化合物及其应用 |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| EP4701658A1 (en) | 2023-04-27 | 2026-03-04 | GlaxoSmithKline Biologicals S.A. | Influenza virus vaccines |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| EP4713483A1 (en) | 2023-05-16 | 2026-03-25 | CureVac RNA Printer GmbH | Improved rna in vitro transcription using dna beads |
| AU2024278682A1 (en) | 2023-05-26 | 2025-11-27 | CureVac SE | Cancer antigens |
| EP4731655A1 (en) | 2023-06-23 | 2026-04-29 | CureVac SE | Nucleic acid encoded antibodies |
| WO2025006851A1 (en) | 2023-06-29 | 2025-01-02 | Nutcracker Therapeutics, Inc. | Ethyl modified rna caps and methods of use |
| AU2024301706A1 (en) | 2023-07-21 | 2026-02-05 | Crispr Therapeutics Ag | Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene |
| WO2025027060A1 (en) | 2023-07-31 | 2025-02-06 | CureVac SE | Nucleic acid encoded runx3 transcription factor |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| IL326176A (en) | 2023-08-01 | 2026-03-01 | BioNTech SE | Ionizable Thiolipids and Their Uses |
| WO2025036992A1 (en) | 2023-08-16 | 2025-02-20 | CureVac SE | Rna conjugates |
| CN117362360A (zh) * | 2023-08-21 | 2024-01-09 | 星锐医药(苏州)有限公司 | 一种帽类似物的制备方法 |
| IL326531A (en) * | 2023-09-06 | 2026-04-01 | Trilink Biotechnologies Llc | Cap analogues and methods of their use |
| WO2025054540A1 (en) | 2023-09-08 | 2025-03-13 | Iovance Biotherapeutics, Inc. | Methods of gene-editing using programmable nucleases |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025071359A1 (ko) | 2023-09-27 | 2025-04-03 | 한미정밀화학 주식회사 | mRNA 캡 유사체 및 이의 용도 |
| WO2025088088A1 (en) | 2023-10-27 | 2025-05-01 | CureVac SE | Rna composition for improving cell therapy |
| TW202540417A (zh) | 2023-11-10 | 2025-10-16 | 美商英特利亞醫療公司 | 用於基因體編輯之組合物、方法及系統 |
| WO2025103803A1 (en) | 2023-11-13 | 2025-05-22 | CureVac SE | Immunotherapy against neuronal and brain tumors |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
| WO2025137301A1 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Methods for rapid engineering of cells |
| TW202525287A (zh) | 2023-12-21 | 2025-07-01 | 德商拜恩技術運輸科技有限責任公司 | 可離子化脂質 |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| WO2025147660A2 (en) | 2024-01-04 | 2025-07-10 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
| CN117534719B (zh) | 2024-01-09 | 2024-05-14 | 北京悦康科创医药科技股份有限公司 | 一种c6'取代锁核酸修饰加帽类似物及其应用 |
| WO2025181704A2 (en) | 2024-02-27 | 2025-09-04 | Crispr Therapeutics Ag | Rt editing compositions and methods |
| WO2025186726A1 (en) | 2024-03-05 | 2025-09-12 | Crispr Therapeutics Ag | Modulating expression of agt (angiotensinogen) gene |
| WO2025201659A1 (en) | 2024-03-28 | 2025-10-02 | BioNTech SE | Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment |
| US12492420B2 (en) | 2024-03-29 | 2025-12-09 | New England Biolabs, Inc. | Compositions, kits, and methods for in vitro transcription |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |
| EP4650358A3 (en) * | 2024-04-26 | 2026-01-14 | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. | Ribose-modified cap analog and use thereof |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
| WO2025242815A1 (en) | 2024-05-23 | 2025-11-27 | CureVac SE | Immunotherapy of squamous cell carcinoma |
| WO2025264662A1 (en) | 2024-06-18 | 2025-12-26 | BioNTech SE | Compositions and methods for treatment of melanoma |
| WO2025262460A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Lipid compositions for nucleic acid delivery |
| WO2026010855A1 (en) | 2024-07-02 | 2026-01-08 | Trilink Biotechnologies, Llc | Modified rna for increasing protein expression |
| WO2026033380A1 (en) | 2024-08-05 | 2026-02-12 | BioNTech SE | Process for preparing oligosaccharide complexes |
| WO2026078020A2 (en) | 2024-10-07 | 2026-04-16 | Explorna Therapeutics Sp. Z O. O. | Efficient in vitro transcription of artificial mrna with highly modified 5' ends |
| EP4722375A1 (en) | 2024-10-07 | 2026-04-08 | ExploRNA Therapeutics Sp. z o. o. | Efficient in vitro transcription of artificial mrna with highly modified 5' ends |
| CN120608113B (zh) * | 2024-11-29 | 2026-04-10 | 上海蓝鹊生物医药有限公司 | 一种合成Cap2结构5'-加帽RNA的组合和方法 |
| CN119306779A (zh) * | 2024-12-13 | 2025-01-14 | 上海科泽永欣生物科技有限公司 | 一种含r构型的起始加帽寡核苷酸引物及其合成方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1997A (en) | 1841-03-03 | Improvement in the mode of rendering fabrics water-proof | ||
| EP0081099A3 (en) * | 1981-12-04 | 1983-08-10 | Sloan-Kettering Institute For Cancer Research | Capped oligonucleotide anti-viral agents |
| DE3148702C2 (de) * | 1981-12-09 | 1985-05-15 | Dieter Gräßlin Feinwerktechnik, 7742 St Georgen | Programmierbare Steuereinrichtung, insbesondere für schaltende Zeitmeßgeräte |
| US5837852A (en) | 1993-10-14 | 1998-11-17 | Bristol-Myers Squibb Company | Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease |
| AU2998800A (en) | 1999-03-24 | 2000-10-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | N-acylphosphoramidites and their use in oligonucleotide synthesis |
| US7074596B2 (en) * | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| US7629325B2 (en) * | 2004-10-11 | 2009-12-08 | Technion Research & Development Foundation Ltd. | Human Sef isoforms and methods of using same for cancer diagnosis and gene therapy |
| EP1819365B1 (en) | 2004-12-09 | 2014-07-02 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inducing an immune response in a mammal and methods of avoiding an immune response to oligonucleotide agents such as short interfering RNAs |
| AU2007268075C1 (en) | 2006-06-01 | 2013-03-07 | Trilink Biotechnologies | Chemically modified oligonucleotide primers for nucleic acid amplification |
| EP2049665A2 (en) * | 2006-07-28 | 2009-04-22 | Applera Corporation | Dinucleotide mrna cap analogs |
| US20080248469A1 (en) | 2006-08-16 | 2008-10-09 | Applera Corporation | Methods for Identifying Nucleotides of Interest in Target Polynucleotides |
| WO2008157688A2 (en) | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| WO2009058911A2 (en) | 2007-10-31 | 2009-05-07 | Applied Biosystems Inc. | Preparation and isolation of 5' capped mrna |
| US9067964B2 (en) | 2008-12-18 | 2015-06-30 | Oligomer Sciences Ab | Complex and method for enhancing nuclear delivery |
| US8557972B2 (en) | 2009-12-21 | 2013-10-15 | University Of Washington Through Its Center For Commercialization | Compositions and methods for transfection of RNA and controlled stabilization of transfected RNA |
| WO2011157617A1 (en) | 2010-06-17 | 2011-12-22 | Febit Holding Gmbh | Complex set of mirna libraries |
| RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| DK2971098T3 (da) | 2013-03-14 | 2019-02-18 | Translate Bio Inc | Kvantitativ bedømmelse for kappe-effektivitet af messenger rna |
| JP6148592B2 (ja) | 2013-10-15 | 2017-06-14 | ヤマハ発動機株式会社 | 車速決定システム、安定制御システム及びそれを備えた鞍乗り型車両 |
| EP3233880A1 (en) | 2014-12-16 | 2017-10-25 | Novartis AG | End capped nucleic acid molecules |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| US11866754B2 (en) | 2015-10-16 | 2024-01-09 | Modernatx, Inc. | Trinucleotide mRNA cap analogs |
| US10487105B2 (en) | 2016-10-19 | 2019-11-26 | Arcturus Therapeutics, Inc. | Trinucleotide MRNA cap analogs |
| KR20200143391A (ko) | 2018-03-15 | 2020-12-23 | 비온테크 알엔에이 파마슈티컬스 게엠베하 | 5'-캡-트리뉴클레오티드- 또는 고차의 올리고뉴클레오티드 화합물 및 이들의 rna 안정화, 단백질 발현 및 치료에서의 사용 |
| US11072808B2 (en) | 2018-10-04 | 2021-07-27 | New England Biolabs, Inc. | Methods and compositions for increasing capping efficiency of transcribed RNA |
| PL248416B1 (pl) | 2020-02-12 | 2025-12-08 | Explorna Therapeutics Spolka Z Ograniczona Odpowiedzialnoscia | Nowe analogi kapu końca 5’ mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| PL432884A1 (pl) | 2020-02-12 | 2021-08-16 | Uniwersytet Warszawski | Nowe analogi kapu końca 5' mRNA, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA i peptydu |
| EP3901261A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| KR20230034333A (ko) | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| KR102366490B1 (ko) | 2020-10-20 | 2022-02-23 | 에스티팜 주식회사 | 5'-캡핑된 rna 합성용 올리고뉴클레오티드 |
-
2016
- 2016-09-20 ES ES22190426T patent/ES2964690T3/es active Active
- 2016-09-20 SI SI201631802T patent/SI4104687T1/sl unknown
- 2016-09-20 EP EP21173278.9A patent/EP3906789B1/en active Active
- 2016-09-20 ES ES21173142T patent/ES2968391T3/es active Active
- 2016-09-20 KR KR1020237004950A patent/KR102670937B1/ko active Active
- 2016-09-20 WO PCT/US2016/052670 patent/WO2017053297A1/en not_active Ceased
- 2016-09-20 DK DK24186081.6T patent/DK4424835T3/da active
- 2016-09-20 PT PT241860816T patent/PT4424835T/pt unknown
- 2016-09-20 CN CN202310734863.0A patent/CN116751827B/zh not_active Ceased
- 2016-09-20 CA CA2999274A patent/CA2999274C/en active Active
- 2016-09-20 CN CN202211046591.7A patent/CN116590285A/zh active Pending
- 2016-09-20 FI FIEP24186081.6T patent/FI4424835T3/fi active
- 2016-09-20 PT PT221753775T patent/PT4104687T/pt unknown
- 2016-09-20 PL PL21173278.9T patent/PL3906789T3/pl unknown
- 2016-09-20 CN CN202311200887.4A patent/CN117025590A/zh active Pending
- 2016-09-20 EP EP25219223.2A patent/EP4717779A2/en active Pending
- 2016-09-20 LT LTEP21173142.7T patent/LT3954225T/lt unknown
- 2016-09-20 FI FIEP22190426.1T patent/FI4140491T3/fi active
- 2016-09-20 EP EP21173142.7A patent/EP3954225B1/en active Active
- 2016-09-20 JP JP2018515136A patent/JP6814997B2/ja active Active
- 2016-09-20 LT LTEP22175377.5T patent/LT4104687T/lt unknown
- 2016-09-20 ES ES22175377T patent/ES2972098T3/es active Active
- 2016-09-20 PL PL16849423T patent/PL3352584T3/pl unknown
- 2016-09-20 CN CN202511246712.6A patent/CN120842296A/zh active Pending
- 2016-09-20 FI FIEP21173278.9T patent/FI3906789T3/fi active
- 2016-09-20 SI SI201631757T patent/SI4140491T1/sl unknown
- 2016-09-20 LT LTEP22190426.1T patent/LT4140491T/lt unknown
- 2016-09-20 EP EP22190426.1A patent/EP4140491B1/en active Active
- 2016-09-20 CN CN202511246658.5A patent/CN121085982A/zh active Pending
- 2016-09-20 EP EP21173131.0A patent/EP3954224A1/en active Pending
- 2016-09-20 PL PL22190426.1T patent/PL4140491T3/pl unknown
- 2016-09-20 HU HUE16849423A patent/HUE055458T2/hu unknown
- 2016-09-20 DK DK21173142.7T patent/DK3954225T5/da active
- 2016-09-20 HU HUE21173142A patent/HUE065331T2/hu unknown
- 2016-09-20 DK DK16849423.5T patent/DK3352584T3/da active
- 2016-09-20 RS RS20210857A patent/RS62129B1/sr unknown
- 2016-09-20 ES ES16849423T patent/ES2879686T3/es active Active
- 2016-09-20 HK HK18114366.7A patent/HK1255236A1/zh unknown
- 2016-09-20 KR KR1020187010893A patent/KR102500198B1/ko active Active
- 2016-09-20 PT PT221904261T patent/PT4140491T/pt unknown
- 2016-09-20 DK DK21173278.9T patent/DK3906789T5/da active
- 2016-09-20 LT LTEP16849423.5T patent/LT3352584T/lt unknown
- 2016-09-20 ES ES21173278T patent/ES2968335T3/es active Active
- 2016-09-20 SI SI201631772T patent/SI3906789T1/sl unknown
- 2016-09-20 FI FIEP22175377.5T patent/FI4104687T3/fi active
- 2016-09-20 PT PT211731427T patent/PT3954225T/pt unknown
- 2016-09-20 DK DK22175377.5T patent/DK4104687T5/da active
- 2016-09-20 CA CA3218662A patent/CA3218662A1/en active Pending
- 2016-09-20 PL PL21173142.7T patent/PL3954225T3/pl unknown
- 2016-09-20 EP EP23192203.0A patent/EP4276189B1/en active Active
- 2016-09-20 EP EP22175377.5A patent/EP4104687B1/en active Active
- 2016-09-20 CN CN202110537080.4A patent/CN113584020A/zh active Pending
- 2016-09-20 LT LTEP24186081.6T patent/LT4424835T/lt unknown
- 2016-09-20 DK DK22190426.1T patent/DK4140491T5/da active
- 2016-09-20 LT LTEP21173278.9T patent/LT3906789T/lt unknown
- 2016-09-20 PL PL22175377.5T patent/PL4104687T3/pl unknown
- 2016-09-20 HU HUE21173278A patent/HUE065203T2/hu unknown
- 2016-09-20 CN CN202511246578.XA patent/CN121064267A/zh active Pending
- 2016-09-20 KR KR1020247017688A patent/KR20240095306A/ko active Pending
- 2016-09-20 CN CN201680067458.6A patent/CN108366604A/zh active Pending
- 2016-09-20 EP EP16849423.5A patent/EP3352584B1/en active Active
- 2016-09-20 HU HUE22175377A patent/HUE065704T2/hu unknown
- 2016-09-20 HR HRP20211091TT patent/HRP20211091T1/hr unknown
- 2016-09-20 SI SI201631248T patent/SI3352584T1/sl unknown
- 2016-09-20 US US15/761,957 patent/US10913768B2/en active Active
- 2016-09-20 FI FIEP21173142.7T patent/FI3954225T3/fi active
- 2016-09-20 SI SI201631773T patent/SI3954225T1/sl unknown
- 2016-09-20 AU AU2016328645A patent/AU2016328645C1/en active Active
- 2016-09-20 SM SM20210396T patent/SMT202100396T1/it unknown
- 2016-09-20 EP EP24186081.6A patent/EP4424835B1/en active Active
- 2016-09-20 HU HUE22190426A patent/HUE064227T2/hu unknown
- 2016-09-20 PT PT211732789T patent/PT3906789T/pt unknown
- 2016-09-20 PT PT168494235T patent/PT3352584T/pt unknown
-
2018
- 2018-12-26 US US16/232,435 patent/US10519189B2/en active Active
-
2019
- 2019-04-01 US US16/371,317 patent/US10494399B2/en active Active
-
2020
- 2020-11-06 US US17/091,422 patent/US11878991B2/en active Active
- 2020-12-10 JP JP2020204713A patent/JP7082174B2/ja active Active
-
2021
- 2021-07-07 CY CY20211100612T patent/CY1124306T1/el unknown
- 2021-07-19 AU AU2021206780A patent/AU2021206780C1/en active Active
- 2021-08-02 US US17/392,170 patent/US11414453B2/en active Active
-
2022
- 2022-04-22 JP JP2022070512A patent/JP7594563B2/ja active Active
- 2022-05-26 US US17/804,192 patent/US11578095B2/en active Active
-
2023
- 2023-03-29 AU AU2023201915A patent/AU2023201915B2/en active Active
- 2023-09-13 AU AU2023229522A patent/AU2023229522B2/en active Active
- 2023-09-14 US US18/467,224 patent/US12258369B2/en active Active
-
2024
- 2024-01-09 US US18/408,431 patent/US12103944B2/en active Active
- 2024-06-26 JP JP2024102548A patent/JP2024150459A/ja active Pending
-
2025
- 2025-01-17 US US19/028,051 patent/US20250171489A1/en active Pending
- 2025-05-13 AU AU2025203425A patent/AU2025203425A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4104687T5 (da) | Sammensætninger og fremgangsmåder til syntetisering af RNA'er med 5-kappe | |
| DK3864152T3 (da) | Fremgangsmåder og sammensætninger til editering af rna'er | |
| DK3356529T3 (da) | Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa | |
| DK3307872T3 (da) | Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober | |
| DK3635009T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK3302709T3 (da) | Fremgangsmåder og sammensætninger til rna-guidet behandling af hiv-infektion | |
| DK3155101T3 (da) | Sammensætninger og fremgangsmåder til ekspression af CRISPR-leder-RNA´er under anvendelse af H1-promotoren | |
| DK4074331T3 (da) | Sammensætninger og fremgangsmåder til internalisering af enzymer | |
| DK4279084T3 (da) | Materialer og fremgangsmåder til behandling af duchennes muskeldystrofi | |
| DK3368541T3 (da) | Sammensætninger og metoder til inhibiering af arginaseaktivitet | |
| DK3337902T3 (da) | 3'-utr-sekvenser til stabilisering af rna | |
| DK3303317T3 (da) | Fremgangsmåder og sammensætninger til inhibering af interaktionen af menin med MLL-proteiner | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3207130T3 (da) | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| DK3262008T3 (da) | Partikelformede sammensætninger til dannelse af geopolymerer, deres anvendelse og fremgangsmåder til dannelse af geopolymere dermed | |
| DK3394259T3 (da) | Sammensætninger og fremgangsmåder til reducering af tau-ekspression | |
| DK3394272T5 (da) | Sammensætninger og fremgangsmåder til effektiv målretning af transgener | |
| DK3484469T3 (da) | Sammensætninger og fremgangsmåder til potentiering af antimikrober | |
| DK3087184T3 (da) | Fremgangsmåder og sammensætninger til specifik inhibering af glycolatoxidase (hao1) med dobbeltstrenget rna | |
| DK3606929T3 (da) | Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme | |
| DK3319948T3 (da) | Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse | |
| DK3322695T3 (da) | Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse | |
| DK3307878T3 (da) | Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger | |
| DK3661562T3 (da) | Fremgangsmåde til konjugation af cys-mabs |